<DOC>
	<DOC>NCT02917031</DOC>
	<brief_summary>This is a 24 week, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the effects of saxagliptin and sitagliptin on cardiac dimensions and function in patients with type 2 diabetes (T2DM) mellitus and heart failure (HF).</brief_summary>
	<brief_title>Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Male or female, aged ≥18 years at the time of consent Heart failure with LVEF ≤45% within the last 6 months, elevated NTproBNP (&gt;600 pg/mL), and stable doses of HF medications that have not increased or decreased for ≥8 weeks prior to screening T2DM with HbA1c ≥7.0% and ≤9.0% (HbA1c ≥7.5% and ≤9.0% for patients treated with sulfonylurea agents) and stable doses of diabetes medications that have not increased or decreased for ≥8 weeks prior to screening Normal sinus rhythm Body mass index ≤40 kg/m2 MRI contraindications: all implanted defibrillators; implanted pacemakers and other devices/implants that in the judgment of the investigator preclude an MRI evaluation eGFR &lt;30 mL/min/1.73 m2 Receiving incretin therapy (DPP4 inhibitors, GLP1 mimetics), or having received incretin therapy within the previous 3 months of screening Receiving therapy with a TZD or having received TZD therapy within the previous 3 months of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Saxagliptin</keyword>
	<keyword>Sitagliptin</keyword>
</DOC>